Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is a recently described immunotherapy-responsive panencephalitis with characteristic features that include a psychiatric onset and a later movement disorder. This entity was first described as a paraneoplastic phenomenon in young women with ovarian teratomata. However, more recently it has become clear that the majority of patients, particularly children, do not harbor a tumor and that males can also be affected. With the development of the NMDAR antibody assay, now available worldwide, a few patients with classical limbic encephalitis and early psychosis and epilepsy have also been found to harbor these antibodies. Early diagnosis followed by immunotherapies and tumor removal, when relevant, expedite recovery from the condition. Antibody levels correlate with the clinical severity of the disease in individual patients, and the antibodies have been shown to substantially reduce NMDA receptors on hippocampal neurons both in vitro and in vivo, supporting the likely direct pathogenicity of the NMDAR antibodies.

Original publication

DOI

10.1007/s11910-011-0186-y

Type

Journal article

Journal

Curr Neurol Neurosci Rep

Publication Date

06/2011

Volume

11

Pages

298 - 304

Keywords

Adolescent, Adult, Autoantibodies, Disease Progression, Encephalitis, Epilepsy, Female, Humans, Immunotherapy, Male, Ovarian Neoplasms, Phenotype, Receptors, N-Methyl-D-Aspartate, Teratoma, Young Adult